NASDAQ:CRBP Corbus Pharmaceuticals Q3 2025 Earnings Report $5.72 -0.13 (-2.29%) As of 03:24 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Corbus Pharmaceuticals EPS ResultsActual EPS-$1.90Consensus EPS -$1.80Beat/MissMissed by -$0.10One Year Ago EPSN/ACorbus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.11 millionBeat/MissN/AYoY Revenue GrowthN/ACorbus Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time8:00AM ETUpcoming EarningsCorbus Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Corbus Pharmaceuticals Earnings HeadlinesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 30, 2026 | americanbankingnews.comCorbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed in Tempo-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerSeptember 29, 2026 | marketscreener.comMFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises new questions about how protected everyday bank accounts and retirement savings really are.October 6 at 1:00 AM | Priority Gold (Ad)Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal CancerSeptember 29, 2026 | globenewswire.comWedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)September 17, 2026 | theglobeandmail.comCorbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy TranscriptSeptember 14, 2026 | seekingalpha.comSee More Corbus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email. Email Address About Corbus PharmaceuticalsCorbus Pharmaceuticals (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases, with an emphasis on oncology and immunology. The company’s research programs are designed to address biological pathways involved in tumor growth, disease progression and immune regulation. Corbus’ oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an investigational monoclonal antibody that targets integrins involved in tumor biology and the tumor microenvironment. The company has also advanced earlier immunology programs, including lenabasum, an oral cannabinoid receptor type 2 agonist that was investigated in inflammatory and fibrotic diseases. Founded in 2009 and headquartered in Norwood, Massachusetts, Corbus conducts research and clinical development activities through its U.S. operations and collaborations. The company is led by Yuval Cohen, Ph.D., who serves as chief executive officer and has guided Corbus through its strategic expansion into oncology.View Corbus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Lamb Weston’s Turnaround Is Starting to Look RealAI Chip Demand Gives Linde a New Growth CatalystInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02 Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
